Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BridgeBio Pharma Inc (BBIO) vs Best Buy Co Inc (BBY) Price & Performance

BridgeBio Pharma IncTrade
Best Buy Co IncTrade

Price performance (Past 24H)

Key statistics

BridgeBio Pharma Inc vs Best Buy Co Inc — how do they compare? BridgeBio Pharma Inc trades at $83.47 (market cap $16.36B), while Best Buy Co Inc trades at $83.44 (market cap $17.55B). The key difference: BridgeBio Pharma Inc and Best Buy Co Inc are close in size by market cap, and Best Buy Co Inc pays a 4.61% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.

BBIOBBY
Market Cap
$16.36B$17.55B
Sector
HealthConsumer Cyclical
52-Week High
$90.17$90.17
52-Week Low
$47.29$55.52
Enterprise Value
$18.14B$19.93B
Dividend Yield
4.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BridgeBio Pharma Inc

BridgeBio Pharma (BBIO) trades at $84.67, up 0.22% today, with a bullish technical signal and strong analyst consensus. Despite missing Q2 2026 EPS estimates with a loss of $0.78 per share, revenue beat expectations as Attruby sales surged 311% year-over-year. The company maintains a high gross margin of 94.44% but reports negative net income and cash flow from operations, reflecting its growth investment phase.

The outlook is optimistic due to multiple late-stage pipeline catalysts, including three potential product launches by mid-2027 and an FDA decision on encaleret by May 2027. Risks include sustained cash burn, high debt of $1.72 billion, and clinical trial execution. The consensus price target of $104.56 implies significant upside if commercial execution succeeds.

Best Buy Co Inc

BBY trades at $82.43, up 0.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 39.1% ROE and trades at a P/E of 15.42, below the sector average. Recent news includes leadership changes and store format tests aimed at growth.

Outlook is mixed: analyst consensus is a hold with a $84.31 price target, but risks include declining revenue and competitive pressures. Upside potential exists if new strategies boost sales, while downside is capped by solid cash flow and dividend payments.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO

About Best Buy Co Inc

With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.

Read more on BBY